The Association of the British Pharmaceutical Industry (ABPI) called for the UK to remain part of the EU today. The industry group - which represents drug manufacturers - argued that a ‘yes’ vote would mean licensing of medicines in Wales, England and Scotland would have to be conducted by a local agency rather than the EMA.
CEO Mark Thompson said: “If we left the EU this would mean that the licensing of new medicines would have to be handled by a UK agency as well as a European agency.
“Our members have confirmed that the applications for UK license would come after the European license due to the smaller patient population in the UK.”
The comments are in line with those made by other UK pharmaceutical industry organisations and current GSK CEO, Andrew Witty.
More to follow...